Cannabis Induces a Clinical Response in Patients with Crohn’s Disease: A Prospective Placebo-Controlled Study.
Clinical Gastroenterology & Hepatology 2013
TIMNA NAFTALI,* LIHI BAR-LEV SCHLEIDER,‡ IRIS DOTAN,§ EPHRAIM PHILIP LANSKY,jj
FABIANA SKLEROVSKY BENJAMINOV,* and FRED MEIR KONIKOFF*
*Department of Gastroenterology and Hepatology, Meir Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Kfar Saba; ‡Tikun Olam for Promotion of Medical Cannabis, Tel Aviv; §IBD Center, Department of Gastroenterology, Sourasky Medical Center, Tel Aviv; and jjLaboratory of Applied Metabolomics and Pharmacognosy, Institute of Evolution, University of Haifa, Haifa, Israel.
Dr. Naftali and a team of researchers used Tikun Olam’s Erez strain to produce dramatic results in the world’s first randomized, placebo-controlled, double-blind study. 45% of Crohn’s patients achieving “complete remission” and 90% reported Significant Reduction of Crohn’s Disease Symptoms with no side effects.
STUDY POPULATION: 21 patients with Crohn’s Disease
STRAIN: EREZ ROLLS VS PLACEBO
Complete remission (CDAI score, <150) was achieved by 5 of 11 subjects in the cannabis group(45%) and 1 of 10 in the placebo group (10%; P = .43). A clinical response (decrease in CDAI score of >100) was observed in 10 of 11 subjects in the cannabis group (90%; from 330 ± 105 to 152 ±109) and 4 of 10 in the placebo group (40%; from 373 ± 94 to 306 ± 143; P=.028). Three patients in the cannabis group were weaned from steroid dependency. Subjects receiving cannabis reported improved appetite and sleep, with no significant side effects.